Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)

Markus Ruhnke; Gerhard Behre; Dieter Buchheidt; Maximilian Christopeit; Axel Hamprecht; Werner Heinz; Claus-Peter Heussel; Marius Horger; Oliver Kurzai; Meinolf Karthaus; Jürgen Löffler; Georg Maschmeyer; Olaf Penack; Christina Rieger; Volker Rickerts; Jörg Ritter; Martin Schmidt-Hieber; Nikolai Schuelper; Stefan Schwartz; Andrew Ullmann; Jörg Janne Vehreschild; Marie von Lilienfeld-Toal; Thomas Weber; Hans H Wolf

doi:10.1111/myc.12838

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)

Standard

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). / Ruhnke, Markus; Behre, Gerhard; Buchheidt, Dieter; Christopeit, Maximilian; Hamprecht, Axel; Heinz, Werner; Heussel, Claus-Peter; Horger, Marius; Kurzai, Oliver; Karthaus, Meinolf; Löffler, Jürgen; Maschmeyer, Georg; Penack, Olaf; Rieger, Christina; Rickerts, Volker; Ritter, Jörg; Schmidt-Hieber, Martin; Schuelper, Nikolai; Schwartz, Stefan; Ullmann, Andrew; Vehreschild, Jörg Janne; von Lilienfeld-Toal, Marie; Weber, Thomas; Wolf, Hans H.

In: MYCOSES, Vol. 61, No. 11, 11.2018, p. 796-813.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Ruhnke, M, Behre, G, Buchheidt, D, Christopeit, M, Hamprecht, A, Heinz, W, Heussel, C-P, Horger, M, Kurzai, O, Karthaus, M, Löffler, J, Maschmeyer, G, Penack, O, Rieger, C, Rickerts, V, Ritter, J, Schmidt-Hieber, M, Schuelper, N, Schwartz, S, Ullmann, A, Vehreschild, JJ, von Lilienfeld-Toal, M, Weber, T & Wolf, HH 2018, 'Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)', MYCOSES, vol. 61, no. 11, pp. 796-813. https://doi.org/10.1111/myc.12838

APA

Ruhnke, M., Behre, G., Buchheidt, D., Christopeit, M., Hamprecht, A., Heinz, W., Heussel, C-P., Horger, M., Kurzai, O., Karthaus, M., Löffler, J., Maschmeyer, G., Penack, O., Rieger, C., Rickerts, V., Ritter, J., Schmidt-Hieber, M., Schuelper, N., Schwartz, S., ... Wolf, H. H. (2018). Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). MYCOSES, 61(11), 796-813. https://doi.org/10.1111/myc.12838

Vancouver

Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W et al. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). MYCOSES. 2018 Nov;61(11):796-813. https://doi.org/10.1111/myc.12838

Bibtex

@article{7bac42b90e3248e8a74819237ae01c0b,

title = "Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)",

abstract = "Invasive fungal diseases (IFD) are a primary cause of morbidity and mortality in patients with haematological malignancies. These infections are mostly life-threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. However, other Non-Aspergillus moulds are increasingly identified in case of documented IFD. For definite diagnosis of IFD, a combination of diagnostic tools have to be applied, including conventional mycological culture and non-conventional microbiological tests such as antibody/antigen and molecular tests, as well as histopathology and radiology. Although varying widely in cancer patients, the risk of invasive fungal infection is highest in those with allogeneic stem cell transplantation and those with acute leukaemia and markedly lower in patients with solid cancer. Since the last edition of Diagnosis of Invasive Fungal Diseases recommendations of the German Society for Hematology and Oncology in 2012, integrated care pathways have been proposed for the management and therapy of IFDs with either a diagnostic driven strategy as opposed to a clinical or empirical driven strategy. This update discusses the impact of this additional evidence and effective revisions.",

keywords = "Antifungal Agents, Fungi, Germany, Hematology, Humans, Invasive Fungal Infections, Medical Oncology, Practice Guidelines as Topic, Journal Article, Review",

author = "Markus Ruhnke and Gerhard Behre and Dieter Buchheidt and Maximilian Christopeit and Axel Hamprecht and Werner Heinz and Claus-Peter Heussel and Marius Horger and Oliver Kurzai and Meinolf Karthaus and J{\"u}rgen L{\"o}ffler and Georg Maschmeyer and Olaf Penack and Christina Rieger and Volker Rickerts and J{\"o}rg Ritter and Martin Schmidt-Hieber and Nikolai Schuelper and Stefan Schwartz and Andrew Ullmann and Vehreschild, {J{\"o}rg Janne} and {von Lilienfeld-Toal}, Marie and Thomas Weber and Wolf, {Hans H}",

note = "{\textcopyright} 2018 Blackwell Verlag GmbH.",

year = "2018",

month = nov,

doi = "10.1111/myc.12838",

language = "English",

volume = "61",

pages = "796--813",

journal = "MYCOSES",

issn = "0933-7407",

publisher = "Wiley-Blackwell",

number = "11",

}

RIS

TY - JOUR

T1 - Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)

AU - Ruhnke, Markus

AU - Behre, Gerhard

AU - Buchheidt, Dieter

AU - Christopeit, Maximilian

AU - Hamprecht, Axel

AU - Heinz, Werner

AU - Heussel, Claus-Peter

AU - Horger, Marius

AU - Kurzai, Oliver

AU - Karthaus, Meinolf

AU - Löffler, Jürgen

AU - Maschmeyer, Georg

AU - Penack, Olaf

AU - Rieger, Christina

AU - Rickerts, Volker

AU - Ritter, Jörg

AU - Schmidt-Hieber, Martin

AU - Schuelper, Nikolai

AU - Schwartz, Stefan

AU - Ullmann, Andrew

AU - Vehreschild, Jörg Janne

AU - von Lilienfeld-Toal, Marie

AU - Weber, Thomas

AU - Wolf, Hans H

PY - 2018/11

Y1 - 2018/11

N2 - Invasive fungal diseases (IFD) are a primary cause of morbidity and mortality in patients with haematological malignancies. These infections are mostly life-threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. However, other Non-Aspergillus moulds are increasingly identified in case of documented IFD. For definite diagnosis of IFD, a combination of diagnostic tools have to be applied, including conventional mycological culture and non-conventional microbiological tests such as antibody/antigen and molecular tests, as well as histopathology and radiology. Although varying widely in cancer patients, the risk of invasive fungal infection is highest in those with allogeneic stem cell transplantation and those with acute leukaemia and markedly lower in patients with solid cancer. Since the last edition of Diagnosis of Invasive Fungal Diseases recommendations of the German Society for Hematology and Oncology in 2012, integrated care pathways have been proposed for the management and therapy of IFDs with either a diagnostic driven strategy as opposed to a clinical or empirical driven strategy. This update discusses the impact of this additional evidence and effective revisions.

AB - Invasive fungal diseases (IFD) are a primary cause of morbidity and mortality in patients with haematological malignancies. These infections are mostly life-threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. However, other Non-Aspergillus moulds are increasingly identified in case of documented IFD. For definite diagnosis of IFD, a combination of diagnostic tools have to be applied, including conventional mycological culture and non-conventional microbiological tests such as antibody/antigen and molecular tests, as well as histopathology and radiology. Although varying widely in cancer patients, the risk of invasive fungal infection is highest in those with allogeneic stem cell transplantation and those with acute leukaemia and markedly lower in patients with solid cancer. Since the last edition of Diagnosis of Invasive Fungal Diseases recommendations of the German Society for Hematology and Oncology in 2012, integrated care pathways have been proposed for the management and therapy of IFDs with either a diagnostic driven strategy as opposed to a clinical or empirical driven strategy. This update discusses the impact of this additional evidence and effective revisions.

KW - Antifungal Agents

KW - Fungi

KW - Germany

KW - Hematology

KW - Humans

KW - Invasive Fungal Infections

KW - Medical Oncology

KW - Practice Guidelines as Topic

KW - Journal Article

KW - Review

U2 - 10.1111/myc.12838

DO - 10.1111/myc.12838

M3 - SCORING: Review article

C2 - 30098069

VL - 61

SP - 796

EP - 813

JO - MYCOSES

JF - MYCOSES

SN - 0933-7407

IS - 11

ER -